Premium
P1‐053: PHARMACOKINETICS AND SAFETY PROFILE OF INTRAVENOUS ADMINISTRATION OF ALLOPREGNANOLONE IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE
Author(s) -
Hernandez Gerson D.,
Lopez Claudia,
Desai Maunil K.,
Kono Naoko,
Irwin Ronald W.,
Rodgers Kathleen E.,
Mack Wendy J.,
Rogawski Michael A.,
Schneider Lon S.,
Brinton Roberta Diaz
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.055
Subject(s) - medicine , tolerability , allopregnanolone , pharmacokinetics , cmax , adverse effect , placebo , clinical trial , anesthesia , neuroactive steroid , receptor , gabaa receptor , alternative medicine , pathology
weeks 8, 12, 18, and 24 (all, P<0.05). An analysis of higher-order domains demonstrated that memantine+ChEI treatment conferred significant effects on memory and language vs placebo+ChEI at weeks 12, 18, and 24 (Figures 1 and 2). On the higher-order domain of praxis, memantine+ChEI showed significant effects vs placebo+ChEI at all timepoints (weeks 4, 8, 12, 18, and 24; Figure 3). Conclusions: The combination of memantine with a ChEI produced early and consistent improvements in cognition for patients with moderate to severe AD. Analysis of higher-order domains on the SIB further supported the efficacy of memantine in maintaining key cognitive functions (memory, language, and praxis), even when these patients are receiving the standard of ongoing ChEI treatment. Funding: Allergan plc.